http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009515824-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-9486 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-94 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-196 |
| filingDate | 2006-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009515824-A |
| titleOfInvention | Development of prodrugs with nitric oxide donors (diazen-1-ium-1,2-diolate moieties) using in vitro / computer prediction |
| abstract | The present invention provides a method using a physiologically based pharmacokinetic model, comprising a prodrug molecule comprising therapeutic agent X (eg, non-steroidal anti-inflammatory drug (NSAID)) and a suitable nitric oxide donor NO (NO-X) is to be selected. The NSAID may be a non-selective or selective cyclooxygenase inhibitor or other biocompatible compound with a carboxyl group. The pharmacokinetic model uses in vitro and / or computer data to infer the optimal combination of parameters. The parameter predicts whether a particular NO-X candidate can provide the desired therapeutic effect (eg, enhanced anti-inflammatory activity, reduced gut, heart, and kidney toxicity). Thus, the present invention greatly enhances the reasonable selection of suitable candidates suitable for drug development, thereby minimizing development time and reducing costs. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017531018-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020023556-A |
| priorityDate | 2005-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 484.